Finding the place of histone deacetylase inhibitors in prostate cancer therapy Journal Article
| Authors: | Marrocco-Tallarigo, D. L.; Centenera, M. M.; Scher, H. I.; Tilley, W. D.; Butler, L. M. |
| Article Title: | Finding the place of histone deacetylase inhibitors in prostate cancer therapy |
| Abstract: | Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological malignancies and solid tumors. In the case of prostate cancer, HDACIs are effective at inhibiting proliferation and inducing apoptosis in a range of in vitro and in vivo experimental models. Recent studies have revealed that the actions of HDACIs in prostate cancer cells extend beyond regulation of histone acetylation and affect proteins involved in maintaining cellular homeostasis and tumor progression, including the androgen receptor, p21<sup>WAF1</sup> and VEGF. The broad spectrum of HDACI targets has allowed rational design of combinations with other therapeutic agents to target multiple pathways involved in prostate cancer progression, including angiogenesis and androgen signaling. In particular, synergistic inhibition of prostate cancer cell growth has been demonstrated using HDACIs in combination with radio- and chemo-therapy, Apo2L/TRAIL, angiogenesis inhibitors, heat-shock protein 90 inhibitors and androgen receptor antagonists. This review examines the current understanding of the actions of HDACIs in prostate cancer cells, both in a laboratory and a clinical context and discusses the potential utility of combination strategies for the treatment of prostate cancer. © 2009 Expert Reviews Ltd. |
| Keywords: | vasculotropin; protein expression; unclassified drug; histone deacetylase inhibitor; clinical trial; fatigue; review; drug potentiation; nonhuman; drug targeting; gemcitabine; cancer radiotherapy; unindexed drug; enzyme inhibition; protein targeting; antineoplastic activity; docetaxel; prostate cancer; drug mechanism; cardiotoxicity; cancer cell; tumor necrosis factor related apoptosis inducing ligand; semaxanib; vorinostat; histone deacetylase inhibitors; heat shock protein 90; nausea and vomiting; androgen receptor; bicalutamide; neurologic disease; antiangiogenic activity; n (2 aminophenyl) 4 [4 (3 pyridinyl) 2 pyrimidinylaminomethyl]benzamide; panobinostat; romidepsin; clinical trials; valproic acid; histone deacetylase; n (2 aminophenyl) 4 (3 pyridinylmethoxycarbonylaminomethyl)benzamide; androgen signaling; combination therapies; 4 [n (2 hydroxyethyl) n [2 (3 indolyl)ethyl]aminomethyl]cinnamohydroxamic acid; 4 n acetyldinaline; amidohydrolase inhibitor; belinostat; butyric acid; cg 1521; sb 379872a; sb 429201; sk 7041; sk 7068; trapoxin; trichostatin a; tubacin; acetylation |
| Journal Title: | Expert Review of Clinical Pharmacology |
| Volume: | 2 |
| Issue: | 6 |
| ISSN: | 1751-2433 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-11-01 |
| Start Page: | 619 |
| End Page: | 630 |
| Language: | English |
| DOI: | 10.1586/ecp.09.44 |
| PROVIDER: | scopus |
| PUBMED: | 22112256 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "Source: Scopus" |
